Welcome to LookChem.com Sign In|Join Free
  • or
2-Methylthio-4-pyrimidinol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

5751-20-2

Post Buying Request

5751-20-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

5751-20-2 Usage

Chemical Properties

White Solid

Uses

A competitive inhibitor of Nitric Oxide Synthase (NOS).

Check Digit Verification of cas no

The CAS Registry Mumber 5751-20-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,7,5 and 1 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 5751-20:
(6*5)+(5*7)+(4*5)+(3*1)+(2*2)+(1*0)=92
92 % 10 = 2
So 5751-20-2 is a valid CAS Registry Number.
InChI:InChI=1/C5H6N2OS/c1-9-5-6-3-2-4(8)7-5/h2-3H,1H3,(H,6,7,8)

5751-20-2 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (M2355)  2-Methylthio-4-pyrimidinol  >98.0%(HPLC)(T)

  • 5751-20-2

  • 1g

  • 350.00CNY

  • Detail
  • TCI America

  • (M2355)  2-Methylthio-4-pyrimidinol  >98.0%(HPLC)(T)

  • 5751-20-2

  • 5g

  • 1,200.00CNY

  • Detail

5751-20-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(Methylthio)pyrimidin-4(3H)-one

1.2 Other means of identification

Product number -
Other names 2-Methylthiopyrimidin-4-ol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:5751-20-2 SDS

5751-20-2Synthetic route

2-thiouracil
141-90-2

2-thiouracil

methyl iodide
74-88-4

methyl iodide

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
Stage #1: 2-thiouracil; methyl iodide With sodium hydroxide In water at 20℃; for 16h;
Stage #2: With acetic acid In water
100%
Stage #1: 2-thiouracil With sodium hydroxide In water at 60 - 70℃;
Stage #2: methyl iodide In ethanol; water at 30 - 60℃; for 0.333333h;
Stage #3: With acetic acid In ethanol; water at 20℃;
100%
With sodium hydroxide at 20℃; for 18h;99%
n-propyl formylacetate

n-propyl formylacetate

carbamimidothioic acid methyl ester
2986-19-8

carbamimidothioic acid methyl ester

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
In isopropyl alcohol at 35℃;97%
methyl 3-oxopropionate
63857-17-0

methyl 3-oxopropionate

carbamimidothioic acid methyl ester
2986-19-8

carbamimidothioic acid methyl ester

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
In ethanol at 10℃;96%
3-oxo-propionic acid ethyl ester
34780-29-5

3-oxo-propionic acid ethyl ester

carbamimidothioic acid methyl ester
2986-19-8

carbamimidothioic acid methyl ester

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
In methanol at 5℃; for 3h;94.9%
isopropyl formylacetate
108350-20-5

isopropyl formylacetate

carbamimidothioic acid methyl ester
2986-19-8

carbamimidothioic acid methyl ester

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
In methanol at 25℃;93%
n-butyl formylacetate

n-butyl formylacetate

carbamimidothioic acid methyl ester
2986-19-8

carbamimidothioic acid methyl ester

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
In ethanol at 25℃;93%
isobutyl formylacetate

isobutyl formylacetate

carbamimidothioic acid methyl ester
2986-19-8

carbamimidothioic acid methyl ester

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
In ethanol at 25℃;93%
3-oxo-propionic acid tert-butyl ester
108350-21-6

3-oxo-propionic acid tert-butyl ester

carbamimidothioic acid methyl ester
2986-19-8

carbamimidothioic acid methyl ester

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
In ethanol at 25℃;93%
2-thiouracil
141-90-2

2-thiouracil

carbonic acid dimethyl ester
616-38-6

carbonic acid dimethyl ester

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
With tetrabutylammomium bromide; potassium carbonate at 120℃; for 8h;93%
With tetrabutylammomium bromide; potassium carbonate In N,N-dimethyl-formamide at 120℃; for 6h;92.6%
boron dimethyl-trifluoro sulphide
353-43-5

boron dimethyl-trifluoro sulphide

2-chloropyrimidin-4(3H)-one

2-chloropyrimidin-4(3H)-one

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
In neat (no solvent) at 60℃; for 16h; Sealed tube;83%
methyl iodide
74-88-4

methyl iodide

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
Stage #1: 2-thiouracil With sodium methylate In methanol at 20℃; for 0.0833333h;
Stage #2: methyl iodide In methanol
74%
Stage #1: 2-thiouracil With sodium hydroxide In water at 20℃; for 0.333333h;
Stage #2: methyl iodide In tetrahydrofuran; water at 20℃; for 18h; Product distribution / selectivity;
60%
Stage #1: 2-thiouracil With sodium hydroxide In water at 20℃; for 0.333333h;
Stage #2: methyl iodide In tetrahydrofuran; water at 20℃; for 18h; Product distribution / selectivity;
60%
4-(dimethylamino)-2-methylsulfanyl-1,3-diazabuta-1,3-dienium iodide
344361-86-0

4-(dimethylamino)-2-methylsulfanyl-1,3-diazabuta-1,3-dienium iodide

acetyl chloride
75-36-5

acetyl chloride

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
With triethylamine In dichloromethane at 0 - 20℃; for 3h;68%
4-hydroxy-2-mercaptopyrimidine
141-90-2

4-hydroxy-2-mercaptopyrimidine

methyl iodide
74-88-4

methyl iodide

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
With sodium hydroxide In ethanol; water at 30 - 60℃; for 0.333333h;47%
Stage #1: 4-hydroxy-2-mercaptopyrimidine With sodium methylate In methanol at 20℃; for 0.0833333h;
Stage #2: methyl iodide In methanol
trimethyl phosphite
512-56-1

trimethyl phosphite

2-thiouracil
141-90-2

2-thiouracil

A

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

B

2-methylthio-3-methylpyrimidin-4(3H)-one
6327-98-6

2-methylthio-3-methylpyrimidin-4(3H)-one

C

1-methyl-2-methysulfanylpyrimidin-4(1H)-one
6330-98-9

1-methyl-2-methysulfanylpyrimidin-4(1H)-one

D

4-methoxy-2-(methylthio)pyrimidine
76541-59-8

4-methoxy-2-(methylthio)pyrimidine

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 80℃; for 3h; Further byproducts given;A 13%
B 10%
C 35%
D 6%
trimethyl phosphite
512-56-1

trimethyl phosphite

2-thiouracil
141-90-2

2-thiouracil

A

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

B

2-methylthio-3-methylpyrimidin-4(3H)-one
6327-98-6

2-methylthio-3-methylpyrimidin-4(3H)-one

C

1-methyl-2-methysulfanylpyrimidin-4(1H)-one
6330-98-9

1-methyl-2-methysulfanylpyrimidin-4(1H)-one

D

1,3-dimethyl-2-thiouracil
1194-71-4

1,3-dimethyl-2-thiouracil

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 80℃; for 3h; Further byproducts given;A 13%
B 10%
C 35%
D 8%
trimethyl phosphite
512-56-1

trimethyl phosphite

2-thiouracil
141-90-2

2-thiouracil

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 80℃; for 55h;17%
2-(methylsulfanyl)pyrimidin-4-ol
5751-20-2

2-(methylsulfanyl)pyrimidin-4-ol

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
at 226.9℃; Equilibrium constant;
4-(N-benzylcarbamoylethoxy)-2-methylthiopyrimidine
109389-01-7

4-(N-benzylcarbamoylethoxy)-2-methylthiopyrimidine

A

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

B

N-benzylacrylamide
13304-62-6

N-benzylacrylamide

Conditions
ConditionsYield
With sodium hydride; paraffin In tetrahydrofuran
sodium formylacetic acid ethyl ester

sodium formylacetic acid ethyl ester

hydriodide of S-methyl-isothiourea

hydriodide of S-methyl-isothiourea

2-Methylthiouracil
5751-20-2

2-Methylthiouracil

Conditions
ConditionsYield
With sodium hydroxide
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

ethyl 4-(methylamino)piperidine-1-carboxylate
73733-69-4

ethyl 4-(methylamino)piperidine-1-carboxylate

2-[(1-carbethoxy-4-piperidinyl)(methyl)amino]-1H-pyrimidin-4-one

2-[(1-carbethoxy-4-piperidinyl)(methyl)amino]-1H-pyrimidin-4-one

Conditions
ConditionsYield
for 26h; Kinetics;99.4%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

phenylboronic acid
98-80-6

phenylboronic acid

2-(methylsulfanyl)-4-phenylpyrimidine
56734-10-2

2-(methylsulfanyl)-4-phenylpyrimidine

Conditions
ConditionsYield
Stage #1: 2-Methylthiouracil With triethylamine; bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate In 1,4-dioxane at 20℃; for 2h; Inert atmosphere; Sealed tube;
Stage #2: phenylboronic acid With bis-triphenylphosphine-palladium(II) chloride; sodium carbonate In 1,4-dioxane; water at 100℃; for 4h; Suzuki coupling; Inert atmosphere; Sealed tube; chemoselective reaction;
99%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

5-iodo-4-hydroxy-6-methyl-2-methylthiopyrimidine
76510-61-7

5-iodo-4-hydroxy-6-methyl-2-methylthiopyrimidine

Conditions
ConditionsYield
With N-iodo-succinimide In chloroform at 70℃; for 2h;97%
With iodine; sodium hydroxide In water at 80℃; for 7h;87%
With sodium hydroxide; iodine In water at 80℃; for 7h;84%
With N-iodo-succinimide In chloroform at 70℃; Inert atmosphere;50%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

4-Aminobenzonitrile
873-74-5

4-Aminobenzonitrile

4-((4-hydroxypyrimidin-2-yl)amino)benzonitrile
189956-45-4

4-((4-hydroxypyrimidin-2-yl)amino)benzonitrile

Conditions
ConditionsYield
With pyridine at 110℃; for 8h; Reagent/catalyst; Temperature; Industrial scale;97%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

aniline
62-53-3

aniline

2-(phenylamino)pyrimidin-4(3H)-one
158661-55-3

2-(phenylamino)pyrimidin-4(3H)-one

Conditions
ConditionsYield
In diethylene glycol dimethyl ether Heating;96%
In diethylene glycol dimethyl ether at 170℃; for 5h;46%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

3,4,5-trimethoxyphenylboronic Acid
182163-96-8

3,4,5-trimethoxyphenylboronic Acid

2-(methylsulfanyl)-4-(3,4,5-trimethoxyphenyl)pyrimidine
1388177-39-6

2-(methylsulfanyl)-4-(3,4,5-trimethoxyphenyl)pyrimidine

Conditions
ConditionsYield
Stage #1: 2-Methylthiouracil With triethylamine; bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate In 1,4-dioxane at 20℃; for 2h; Inert atmosphere; Sealed tube;
Stage #2: 3,4,5-trimethoxyphenylboronic Acid With bis-triphenylphosphine-palladium(II) chloride; sodium carbonate In 1,4-dioxane; water at 100℃; for 4h; Suzuki coupling; Inert atmosphere; Sealed tube; chemoselective reaction;
96%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

p-toluidine
106-49-0

p-toluidine

2-<(4-methylphenyl)amino>pyrimidin-4(3H)-one

2-<(4-methylphenyl)amino>pyrimidin-4(3H)-one

Conditions
ConditionsYield
In diethylene glycol dimethyl ether Heating;94%
With Trimethylacetic acid at 130℃; Inert atmosphere;
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

3-biphenyl amine
2243-47-2

3-biphenyl amine

2-(3-biphenylamino)pyrimidin-4(3H)-one
960243-28-1

2-(3-biphenylamino)pyrimidin-4(3H)-one

Conditions
ConditionsYield
In diethylene glycol dimethyl ether for 18h; Heating / reflux;92%
In diethylene glycol dimethyl ether for 18h; Heating / reflux;92%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

1-amino-3-methylbenzene
108-44-1

1-amino-3-methylbenzene

2-<(3-methylphenyl)amino>pyrimidin-4(3H)-one

2-<(3-methylphenyl)amino>pyrimidin-4(3H)-one

Conditions
ConditionsYield
In diethylene glycol dimethyl ether Heating;90%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

4-Chloro-2-methylthiopyrimidine
49844-90-8

4-Chloro-2-methylthiopyrimidine

Conditions
ConditionsYield
With thionyl chloride In dichloromethane; N,N-dimethyl-formamide at 40℃; for 3h;87.6%
With thionyl chloride; N,N-dimethyl-formamide In dichloromethane at 40℃; for 3h;87.6%
With trichlorophosphate
With trichlorophosphate
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

2-methylsulfanyl-5-bromopyrimidin-4-one
81560-03-4

2-methylsulfanyl-5-bromopyrimidin-4-one

Conditions
ConditionsYield
With N-Bromosuccinimide In dichloromethane for 6h; Reflux;87%
With potassium hydroxide; bromine; sodium bromide In 1,4-dioxane at 70℃; for 1h;75%
With bromine; acetic acid at 0 - 20℃; for 16h;62%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

acrylonitrile
107-13-1

acrylonitrile

3-(2-cyanoethyl)-2-methylthiopyrimidin-4-one
17994-74-0

3-(2-cyanoethyl)-2-methylthiopyrimidin-4-one

Conditions
ConditionsYield
With pyridine for 7h; Heating;86%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

tributyl(thien-2-yl)stannane
54663-78-4

tributyl(thien-2-yl)stannane

2-thiophen-2-yl-3H-pyrimidin-4-one
125903-92-6

2-thiophen-2-yl-3H-pyrimidin-4-one

Conditions
ConditionsYield
With tetrakis(triphenylphosphine) palladium(0); copper(I) bromide dimethylsulfide complex In tetrahydrofuran for 24h; Liebeskind-Srogl cross-coupling; Inert atmosphere; Reflux;84%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

3-amino-4-methyl benzoic acid methyl ester
18595-18-1

3-amino-4-methyl benzoic acid methyl ester

methyl 3-(4-oxopyrimidin-2-ylamino)-4-methylbenzoate
1451042-82-2

methyl 3-(4-oxopyrimidin-2-ylamino)-4-methylbenzoate

Conditions
ConditionsYield
With hydrogenchloride In water at 130 - 160℃; for 1.5h; Reagent/catalyst; Temperature; Time; Inert atmosphere;84%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

4-bromo-2-methylsulfanylpyrimidine
959236-97-6

4-bromo-2-methylsulfanylpyrimidine

Conditions
ConditionsYield
With phosphorus(V) oxybromide In acetonitrile at 80℃; for 5h;83%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

1,3-dibromo-propane
109-64-8

1,3-dibromo-propane

3-(3-bromopropyl)-S-methyl-2-thiouracil
122182-81-4

3-(3-bromopropyl)-S-methyl-2-thiouracil

Conditions
ConditionsYield
With sodium hydride In N,N-dimethyl-formamide 1h, RT; 60 deg C, 24 h;82%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

4-chloro-aniline
106-47-8

4-chloro-aniline

2-<(4-chlorophenyl)amino>pyrimidin-4(3H)-one

2-<(4-chlorophenyl)amino>pyrimidin-4(3H)-one

Conditions
ConditionsYield
In diethylene glycol dimethyl ether Heating;79%
With 2-ethoxy-ethanol
With Trimethylacetic acid at 130℃; Inert atmosphere;
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

4-amino-benzoic acid
150-13-0

4-amino-benzoic acid

4-(6-oxo-1,6-dihydro-pyrimidin-2-ylamino)-benzoic acid
919116-69-1

4-(6-oxo-1,6-dihydro-pyrimidin-2-ylamino)-benzoic acid

Conditions
ConditionsYield
In diglyme (diethyleneglycol dimethylether) for 16h; Heating / reflux;79%
In diethylene glycol dimethyl ether for 16h; Heating / reflux;
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

3-chloro-aniline
108-42-9

3-chloro-aniline

2-<(3-chlorophenyl)amino>pyrimidin-4(3H)-one

2-<(3-chlorophenyl)amino>pyrimidin-4(3H)-one

Conditions
ConditionsYield
In diethylene glycol dimethyl ether Heating;77%
In diethylene glycol dimethyl ether for 18h; Heating / reflux;66%
2-Methylthiouracil
5751-20-2

2-Methylthiouracil

3,4-(methylenedioxy)-benzeneboronic acid
94839-07-3

3,4-(methylenedioxy)-benzeneboronic acid

4-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfanyl)pyrimidine
1388177-38-5

4-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfanyl)pyrimidine

Conditions
ConditionsYield
Stage #1: 2-Methylthiouracil With triethylamine; bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate In 1,4-dioxane at 20℃; for 2h; Inert atmosphere; Sealed tube;
Stage #2: 3,4-(methylenedioxy)-benzeneboronic acid With bis-triphenylphosphine-palladium(II) chloride; sodium carbonate In 1,4-dioxane; water at 100℃; for 4h; Suzuki coupling; Inert atmosphere; Sealed tube; chemoselective reaction;
77%

5751-20-2Relevant academic research and scientific papers

Sulfenyl Ynamides in Gold Catalysis: Synthesis of Oxo-functionalised 4-aminoimidazolyl Fused Compounds by Intermolecular Annulation Reactions

Arce, Elsa M.,Lamont, Scott G.,Davies, Paul W.

, p. 2503 - 2509 (2020/04/30)

Functionalised N-heterocyclic pyridinium N-aminides have been designed and synthesised to evaluate a nitrenoid-based annulation strategy into imidazole-fused oxo-substituted frameworks of importance to medicinal and agrochemical discovery programmes. Sulfenyl substituted ynamides were identified as privileged reactants affording productive gold-catalysed annulation reactions with these and other nitrenoids. This annulation method provides selective and efficient access into geminally amino-sulfenyl substituted nitrogen heterocycles under mild reaction conditions. (Figure presented.).

Scaffold hopping in discovery of HIV-1 non-nucleoside reverse transcriptase inhibitors: From CH(CN)-DABOs to CH(CN)-dapys

Chen, Fen-Er,Li, Ting-Ting,Pannecouque, Christophe,Zhuang, Chun-Lin,de Clercq, Erik

, (2020/04/10)

Scaffold hopping is a frequently-used strategy in the development of non-nucleoside reverse transcriptase inhibitors. Herein, CH(CN)-DAPYs were designed by hopping the cyano-methylene linker of our previous published CH(CN)-DABOs onto the etravirine (ETR). Eighteen CH(CN)-DAPYs were synthesized and evaluated for their anti-HIV activity. Most compounds exhibited promising activity against wild-type (WT) HIV-1. Compounds B4 (EC50 = 6 nM) and B6 (EC50 = 8 nM) showed single-digit nanomolar potency against WT HIV-1. Moreover, these two compounds had EC50 values of 0.06 and 0.08 μM toward the K103N mutant, respectively, which were comparable to the reference efavirenz (EFV) (EC50 = 0.08 μM). The preliminary structure-activity relationship (SAR) indicated that introducing substitutions on C2 of the 4-cyanophenyl group could improve antiviral activity. Molecular docking predicted that the cyano-methylene linker was positioned into the hydrophobic cavity formed by Y181/Y188 and V179 residues.

Design of biphenyl-substituted diarylpyrimidines with a cyanomethyl linker as HIV-1 NNRTIs via a molecular hybridization strategy

Chen, Fen-Er,Han, Sheng,Lei, Yuan,Pannecouque, Christophe,Yang, Yang,Zhuang, Chunlin,de Clercq, Erik

, (2020/03/17)

The key problems of human immunodeficiency virus (HIV) therapy are the rapid emergence of drug-resistant mutant strains and significant cumulative drug toxicities. Therefore, there is an urgent demand for new anti-HIV agents with low toxicity and broad-spectrum antiviral potency. A series of biphenyl-substituted diarylpyrimidines with a cyanomethyl linker were designed using a molecular hybridization strategy. The cell-based anti-HIV assay showed that most of the compounds exhibited moderate to good activities against wild-type HIV-1 and clinically relevant mutant strains with a more favorable toxicity, and the enzymatic assay showed they had nanomolar activity against reverse transcriptase (RT). Compound 10p exhibited the best activity against wild-type HIV-1 with an EC50 (50% HIV-1 replication inhibitory concentration) value of 0.027 μM, an acceptable CC50 (50% cytotoxic concentration) value of 36.4 μM, and selectivity index of 1361, with moderate activities against the single mutants (EC50: E138K, 0.17 μM; Y181C, 0.87 μM; K103N, 0.9 μM; L100I, 1.21 μM, respectively), and an IC50 value of 0.059 μM against the RT enzyme, which was six-fold higher than nevirapine (NVP). The preliminary structure–activity relationship (SAR) of these new compounds was concluded. The molecular modeling predicted the binding modes of the new compounds with RT, providing molecular insight for further drug design.

Synthesis method of 4-chloro-2-methylthiopyrimidine

-

Paragraph 0022; 0023; 0024; 0025-0028; 0037-009, (2019/06/30)

The invention belongs to the technical field of organic synthesis, in particular to a synthesis method of 4-chloro-2-methylthiopyrimidine. The method includes taking 2-thiouracil as a raw material, dimethyl sulfate as a methylation reagent, thionyl chloride and phosphorus oxychloride as a chlorination reagent, and synthesizing the 4-chloro-2-methylthiopyrimidine through methylation and chlorination.The dimethyl sulfate is taken as the methylation reagent to replace methyl bromide or methyl iodide, and thus the safety of the reaction is increased, and the cost is decreased; sodium hydroxide istaken as alkali to replace sodium methoxide or butyl lithium, and thus the safety of the reaction is increased, and the cost is reduced; toluene is taken as a reaction solvent, and thus the dosage ofthe chlorinated reagent is greatly reduced, the reaction safety is greatly improved, the cost is reduced, and the post-treatment operation is simplified; and the sulfoxide chloride and the phosphorusoxychloride are taken as the mixed chlorinating reagent, and thus the reaction yield is greatly improved.

BF3·SMe2 for Thiomethylation, Nitro Reduction and Tandem Reduction/SMe Insertion of Nitrogen Heterocycles

S?derstr?m, Marcus,Zamaratski, Edouard,Odell, Luke R.

, p. 5402 - 5408 (2019/06/27)

Herein, a general, solvent-free and straightforward thiomethylation of electron deficient heterocycles using BF3·SMe2 as a dual thiomethyl source and Lewis acidic activator is presented. A range of heterocycles including pyrimidine, pyrazine, pyridazine, thiazole and purine derivatives were successfully substituted using this method. An unexpected reductive property of BF3·SMe2 towards nitropyridines was also discovered including an intriguing tandem reduction/SMe insertion process in certain substrates. Notable features of the present work include its convenience and use of a non-malodorous reagent while the discovery of novel chemical transformations using BF3·SMe2 provides fundamental new insights into the reactivity of this commonly employed reagent.

A new and efficient protocol for the synthesis of the key intermediate of palbociclib

Li, Shuting,Yang, Wanfeng,Ji, Min,Cai, Jin,Chen, Junqing

, p. 14 - 19 (2019/06/21)

A new and efficient synthesis of 6-bromo-8-cyclopentyl-5-methyl-2-(methylsulfinyl)-pyrido[2,3-d]pyrimidin-7(8H)-one, a key intermediate of Palbociclib, starting from thiouracil was described. This protocol involved methylation, nucleophilic substitution, bromination, nucleophilic substitution, Heck reaction, ring closure, oxidation, and bromination to afford a key intermediate of Palbociclib with approximately 35% overall yield. The advantages of this developed synthetic strategy included improved overall yield, inexpensive starting materials, and readily controllable and cleaner reaction conditions.

NOVEL IN-VIVO PROBE FOR REAL TIME LONGITUDINAL MONITORING OF INDUCIBLE NITRIC-OXIDE SYNTHASE IN LIVING CELLS AND ANIMALS

-

Paragraph 0074, (2018/06/06)

The present disclosure relates to an in vivo fluorescent or radioactive probe represented by a compound of formula I which is capable of longitudinal imaging of inducible nitric oxide synthase (iNOS) expression in living cells and living animals on a real time basis. The probe of the present disclosure can exhibit specific and high affinity binding to the iNOS enzyme with reduced enzyme inhibitory property and also enables longitudinal monitoring of iNOS expression along with its activity or NO production in a same experimental subject throughout the progression of a physiological or disease process without employing separate subjects as controls and experimental. The present disclosure further provides a rapid and inexpensive real time method for visualizing iNOS expression and its activity in living cells and living animals precisely, conveniently and reversibly along with simultaneous in vivo imaging of its catalytic product, nitric oxide (NO) in live physiological settings.

Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR

Lu, Huan-Huan,Xue, Ping,Zhu, Yuan-Yuan,Ju, Xiu-Lian,Zheng, Xiao-Jiao,Zhang, Xun,Xiao, Ting,Pannecouque, Christophe,Li, Ting-Ting,Gu, Shuang-Xi

, p. 2491 - 2497 (2017/04/03)

30 new analogues of diarylpyrimidines were synthesized for further structural modifications, involving not only the linker but also the wing α of DAPYs. The anti-HIV-1 activities of all target molecules were evaluated, and most of them exhibited potent anti-HIV-1 (WT) activities and low cytotoxicities. Among which, compound 4g showed excellent activities against WT HIV-1 with an EC50 value of 5.8?nM and SI of up to 26,034. Another compound 4ab bearing a novel pyridinyl Wing α also displayed attractive activities. The structure-activity relationship (SAR) study was also summarized.

A Palumbo vial preparation method of the key intermediate (by machine translation)

-

Paragraph 0008; 0010, (2018/03/24)

The invention discloses a Palumbo Xilin key intermediate 6 - bromo - 2 - methyl sulfonyl - 8 - cyclopentyl - 5 - methyl pyridine and (2, 3 - d) pyrimidine - 7 (8 H) - ketone. The method uses the thiourea pyrimidine as the starting material, by methylation, chloro, bromo synthesis of 5 - bromo - 4 - chloro - 2 - methylthio-pyrimidine, then with the cyclopentamine alkylation, with 2 - butenoic acid by the heck reaction, then the intramolecular acylation reaction for the synthesis of 2 - methylthio - 8 - cyclopentyl - 5 - methyl pyridine and (2, 3 - d) pyrimidine - 7 (8 H) - one, finally with the NBS reaction for the preparation of 6 - bromo - 2 - methyl sulfonyl - 8 - cyclopentyl - 5 - methyl pyridine and (2, 3 - d) pyrimidine - 7 (8 H) - one. The preparation process of the present invention short step, not using the dangerous process, simple and convenient operation, low cost of raw materials, to meet the using requirements of the people. (by machine translation)

Industrial synthesis method of rilpivirine and intermediate compound

-

Paragraph 0028; 0038-0040, (2017/10/07)

The invention discloses an industrial synthesis method of rilpivirine. A compound as shown in a formula I and compound hydrochloride as shown in a formula VI react to obtain rilpivirine. The invention further discloses an intermediate compound as shown in the formula I and a synthesis method of the intermediate compound. Compared with the prior art, the synthesis method is simple to operate, mild in condition, high in yield and purity and suitable for industrial production.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 5751-20-2